Starpharma (ASX:SPL)
ASX announcement history & article coverage
Transparent by design.
Announcments by Starpharma (ASX:SPL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Starpharma secures majority ownership of Petalion
Trading Halt
Change in substantial holding
Notice of Annual General Meeting/Proxy Form
Change of Director's Interest Notice - C Maley
Application for quotation of securities - SPL
Notification of cessation of securities - SPL
Chair and Deputy Chair Appointments
Ceasing to be a substantial holder
Becoming a substantial holder
Ceasing to be a substantial holder
Annual General Meeting 2026 Date
Becoming a substantial holder
Ceasing to be a substantial holder
2026 Appendix 4G and Corporate Governance Statement
2026 Annual Report
Starpharma advances DEP® platform, secures major partnerships, plans clinical trial for lead radiopharmaceutical, reports FY26 loss of $7.5M
FY26 Key Financial Results and Annual Report
Starpharma FY26 revenue surges 145%, loss narrows, $30M raised to extend funding runway
Preliminary Final Report
Company reports 145% revenue increase and reduced loss for FY 2026 driven by Genentech collaboration
Becoming a substantial holder
Ceasing to be a substantial holder
Change in substantial holding
Change in substantial holding
Change of Director Interest Notice - R Basser
Change of Director Interest Notice - R Thomas
Change of Director Interest Notice - L Cheng
Change of Director Interest Notice - J Davies
Change of Director Interest Notice - C Maley
Becoming a substantial holder
Application for quotation of securities - SPL
Successful Completion of $32 million Entitlement Offer
Starpharma completes $32 million entitlement offer to fund oncology pipeline advancement
Letter to Ineligible Shareholders
Letter to Eligible Shareholders
Ceasing to be a substantial holder